Inventiva (IVA) Competitors $2.48 -0.05 (-1.98%) (As of 12/12/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends IVA vs. XERS, HUMA, ABVX, ANNX, PRTC, TSHA, CRVS, KOD, ARCT, and SANAShould you be buying Inventiva stock or one of its competitors? The main competitors of Inventiva include Xeris Biopharma (XERS), Humacyte (HUMA), ABIVAX Société Anonyme (ABVX), Annexon (ANNX), PureTech Health (PRTC), Taysha Gene Therapies (TSHA), Corvus Pharmaceuticals (CRVS), Kodiak Sciences (KOD), Arcturus Therapeutics (ARCT), and Sana Biotechnology (SANA). These companies are all part of the "pharmaceutical products" industry. Inventiva vs. Xeris Biopharma Humacyte ABIVAX Société Anonyme Annexon PureTech Health Taysha Gene Therapies Corvus Pharmaceuticals Kodiak Sciences Arcturus Therapeutics Sana Biotechnology Inventiva (NASDAQ:IVA) and Xeris Biopharma (NASDAQ:XERS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, community ranking, earnings, dividends, media sentiment, risk and analyst recommendations. Which has stronger earnings & valuation, IVA or XERS? Xeris Biopharma has higher revenue and earnings than Inventiva. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInventiva$15.62M8.33-$119.51MN/AN/AXeris Biopharma$163.91M3.09-$62.26M-$0.45-7.56 Does the MarketBeat Community prefer IVA or XERS? Xeris Biopharma received 123 more outperform votes than Inventiva when rated by MarketBeat users. However, 80.00% of users gave Inventiva an outperform vote while only 69.76% of users gave Xeris Biopharma an outperform vote. CompanyUnderperformOutperformInventivaOutperform Votes2080.00% Underperform Votes520.00% Xeris BiopharmaOutperform Votes14369.76% Underperform Votes6230.24% Does the media prefer IVA or XERS? In the previous week, Inventiva had 2 more articles in the media than Xeris Biopharma. MarketBeat recorded 3 mentions for Inventiva and 1 mentions for Xeris Biopharma. Inventiva's average media sentiment score of 1.87 equaled Xeris Biopharma'saverage media sentiment score. Company Overall Sentiment Inventiva Very Positive Xeris Biopharma Very Positive Is IVA or XERS more profitable? Inventiva has a net margin of 0.00% compared to Xeris Biopharma's net margin of -33.69%. Inventiva's return on equity of 0.00% beat Xeris Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets InventivaN/A N/A N/A Xeris Biopharma -33.69%-16,662.63%-17.38% Do insiders & institutionals have more ownership in IVA or XERS? 19.1% of Inventiva shares are owned by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are owned by institutional investors. 32.0% of Inventiva shares are owned by insiders. Comparatively, 4.6% of Xeris Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more volatility and risk, IVA or XERS? Inventiva has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500. Comparatively, Xeris Biopharma has a beta of 2.65, indicating that its share price is 165% more volatile than the S&P 500. Do analysts rate IVA or XERS? Inventiva presently has a consensus price target of $13.25, suggesting a potential upside of 434.27%. Xeris Biopharma has a consensus price target of $4.87, suggesting a potential upside of 43.14%. Given Inventiva's stronger consensus rating and higher possible upside, equities research analysts clearly believe Inventiva is more favorable than Xeris Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inventiva 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Xeris Biopharma 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 SummaryInventiva beats Xeris Biopharma on 10 of the 15 factors compared between the two stocks. Ad Wall Street StarHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still simple, proof-of-concept systems. For its next act, AI is going to help save lives. Already better than humans at a number of medical tasks, AI is ramping up to completely revolutionize healthcare.Click here to learn more about the booming eHealth industry - and see which microcap will be at the Get Inventiva News Delivered to You Automatically Sign up to receive the latest news and ratings for IVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IVA vs. The Competition Export to ExcelMetricInventivaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$130.14M$6.83B$5.13B$9.23BDividend YieldN/A2.87%5.16%3.99%P/E RatioN/A11.06107.1317.76Price / Sales8.33217.751,299.62127.82Price / CashN/A22.7036.1835.66Price / Book-3.705.274.884.89Net Income-$119.51M$152.46M$116.33M$225.53M7 Day Performance-6.06%-1.69%-0.22%0.23%1 Month Performance-6.06%-7.35%-2.11%3.64%1 Year Performance-43.05%20.64%32.09%27.19% Inventiva Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IVAInventiva3.3268 of 5 stars$2.48-2.0%$13.25+434.3%-43.1%$130.14M$15.62M0.00100Positive NewsGap UpXERSXeris Biopharma3.9195 of 5 stars$3.66-0.3%$4.87+33.0%+82.8%$545.63M$163.91M0.00290Positive NewsHUMAHumacyte3.5653 of 5 stars$4.31-10.8%$13.00+201.6%+55.8%$542.46M$1.57M-3.28150Short Interest ↑ABVXABIVAX Société Anonyme2.2732 of 5 stars$8.54-3.1%$38.67+352.8%-23.8%$541.01MN/A0.0061Short Interest ↑ANNXAnnexon2.4889 of 5 stars$5.03-1.4%$15.80+214.1%+107.7%$536.15MN/A0.0060Positive NewsPRTCPureTech Health1.9136 of 5 stars$22.36+1.2%$45.00+101.3%+26.2%$535.30M$3.33M0.00100Short Interest ↑TSHATaysha Gene Therapies3.9402 of 5 stars$2.58+4.0%$6.63+156.8%+45.5%$528.75M$15.45M4.11180CRVSCorvus Pharmaceuticals2.2858 of 5 stars$8.19-0.8%$12.83+56.7%+403.7%$526.29MN/A0.0030Short Interest ↑KODKodiak Sciences2.9957 of 5 stars$9.96+27.2%$6.80-31.7%+250.6%$524.10MN/A-2.7490Analyst UpgradeHigh Trading VolumeARCTArcturus Therapeutics2.749 of 5 stars$19.21+0.6%$71.40+271.7%-23.3%$520.40M$169.93M0.00180News CoverageSANASana Biotechnology2.6412 of 5 stars$2.30flat$13.50+487.0%-35.7%$513.52MN/A-1.64328 Related Companies and Tools Related Companies XERS Competitors HUMA Competitors ABVX Competitors ANNX Competitors PRTC Competitors TSHA Competitors CRVS Competitors KOD Competitors ARCT Competitors SANA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IVA) was last updated on 12/12/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThis could bring inflation roaring back (I’m concerned)"For AI... We have to produce massive electricity that we don't have. Nuclear has become very safe, very good....The Oxford Club | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredCaught on camera (shocking new AI tech)Everyone is talking about the “Magnificent Seven"... Nvidia, Meta, Google, Microsoft, etc. Meanwhile, they ...Banyan Hill Publishing | SponsoredThis happened before the 1987 crash too…I’d urge you to watch my latest exposé into what’s really going on in the tech sector… why I believe we could ...Porter & Company | SponsoredPrepare Now Before This Looming $2 Trillion D.C. ShockMillions of traders could get blindsided by this election-year shock on December 18th… And if you do nothin...Timothy Sykes | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inventiva S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inventiva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IVA Stock Alerts